Analysis of the efficacy of a carfilzomib-based regimen in the treatment of relapsed and refractory multiple myeloma
10.3760/cma.j.cn112138-20250313-00147
- VernacularTitle:卡非佐米为基础方案治疗复发难治性多发性骨髓瘤的疗效分析
- Author:
Jie ZHOU
1
;
Wenming CHEN
;
Yanchen LI
Author Information
1. 北京朝阳中西医结合急诊抢救医院血液科，北京 100021
- Publication Type:Journal Article
- Keywords:
Multiple myeloma;
Efficacy;
Relapsed/refractory;
Carfilzomib
- From:
Chinese Journal of Internal Medicine
2025;64(9):868-871
- CountryChina
- Language:Chinese
-
Abstract:
A retrospective analysis was conducted on 26 patients with relapsed and refractory multiple myeloma (RRMM) who were treated with carfilzomib-based regimens at Beijing Chaoyang Integrative Medicine Rescue and First Aid Hospital from July 2021 to May 2024. The median number of treatment cycles was 5 (range, 2-8). The overall response rate was 53.8% (14/26). The median follow-up duration was 9.5 months, and the median progression-free survival (PFS) was 8.6 months (range, 1.7-25.2 months). Patients without plasmacytoma recurrence ( n=17) had a PFS of 12.3 months. In contrast, patients with plasmacytoma recurrence ( n=9) had a PFS of 6.2 months. The difference in PFS between these two groups was statistically significant ( P=0.013). Age (over 65 vs. 65 or younger), and treatment line (more than three vs. three or fewer) did not significantly affect treatment efficacy (all P>0.05). Common adverse reactions of grade 3 or higher included hematologic adverse reactions in 10 cases, which improved with symptomatic treatment. Non-hematologic adverse reactions included pulmonary infection (2 cases), renal failure (1 case), and heart failure (1 case). In conclusion, carfilzomib-based regimens demonstrate good clinical efficacy and manageable safety in the treatment of RRMM.
